Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders
Advanced Science · 2023-08 · 10 (23)
DOI: 10.1002/advs.202206910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.06.2023. Verfasst von Lizhao Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd., Duarte, CA, 91010, USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Oligodendrocyte Precursor Cells, Multiple Sclerosis, Canavan Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, California Institute for Regenerative Medicine.
Abstract (Originalsprache)
Demyelinating disorders are among the most common and debilitating diseases in neurology. Canavan disease (CD) is a lethal demyelinating disease caused by mutation of the aspartoacylase ( ASPA ) gene, which leads to the accumulation of its substrate N ‐acetyl‐ l ‐aspartate (NAA), and consequently demyelination and vacuolation in the brain. In this study, hypoimmunogenic human induced pluripotent stem cell (iPSC)‐derived oligodendrocyte progenitor cells (OPC) are developed from a healthy donor as an “off‐the‐shelf” cell therapy. Hypoimmunogenic iPSCs are generated through CRISPR/Cas9 editing of the human leukocyte antigen (HLA) molecules in healthy donor‐derived iPSCs and differentiated into OPCs. The OPCs are engrafted into the brains of CD (nur7) mice and exhibit widespread distribution in the brain. The engrafted OPCs mature into oligodendrocytes that express the endogenous wildtype ASPA gene. Consequently, the transplanted mice exhibit elevated human ASPA expression and enzymatic activity and reduced NAA level in the brain. The transplanted OPCs are able to rescue major pathological features of CD, including defective myelination, extensive vacuolation, and motor function deficits. Moreover, the hypoimmunogenic OPCs exhibit low immunogenicity both in vitro and in vivo. The hypoimmunogenic OPCs can be used as “off‐the‐shelf” universal donor cells to treat various CD patients and many other demyelinating disorders, especially autoimmune demyelinating diseases, such as multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd., Duarte, CA, 91010, USA.
- Department of Immunology and Theranostics, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd., Duarte, CA, 91010, USA.
ORCID-Profile: Yanhong Shi
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- California Institute for Regenerative Medicine
Zitieren
APA
Feng, L., Chao, J., Ye, P., Luong, Q., Sun, G., Liu, W., Cui, Q., Flores, S., Jackson, N., Shayento, A. N. H., Sun, G., Liu, Z., Hu, W., & Shi, Y. (2023). Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders. Advanced Science, 10(23). https://doi.org/10.1002/advs.202206910
Vancouver
Feng L, Chao J, Ye P, Luong Q, Sun G, Liu W, et al. Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders. Advanced Science. 2023;10(23). doi:10.1002/advs.202206910
BibTeX
@article{Feng2023,
author = {Feng, Lizhao and Chao, Jianfei and Ye, Peng and Luong, Qui and Sun, Guoqiang and Liu, Wei and Cui, Qi and Flores, Sergio and Jackson, Natasha and Shayento, Afm Nazmul Hoque and Sun, Guihua and Liu, Zhenqing and Hu, Weidong and Shi, Yanhong},
title = {Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {23},
doi = {10.1002/advs.202206910}
}
EUVIMED